11a-N-Tosyl-5-deoxi-pterocarpan, LQB-223, a novel compound with potent antineoplastic activity toward breast cancer cells with different phenotypes
- 345 Downloads
Multidrug resistance is the major obstacle for successful treatment of breast cancer, prompting the investigation of novel anticancer compounds.
In this study, we tested whether LQB-223, an 11a-N-Tosyl-5-deoxi-pterocarpan newly synthesized compound, could be effective toward breast cancer cells.
Human breast cell lines MCF-7, MDA-MB-231, HB4a and MCF-7 DoxR were used as models for this study. Cell culture, MTT and clonogenic assay, flow cytometry and Western blotting were performed.
The LQB-223 decreased cell viability, inhibited colony formation and induced an expressive G2/M arrest in breast cancer cells. There was an induction in p53 and p21Cip1 protein levels following treatment of wild-type p53 MCF-7 cells, which was not observed in the mutant p53 MDA-MB-231 cell line, providing evidence that the compound might act to modulate the cell cycle regardless of p53 status. In addition, LQB-223 resulted in decreased procaspase levels and increased annexin V staining, suggesting that the apoptotic cascade is also triggered. Importantly, LQB-223 treatment was shown to be less cytotoxic to non-neoplastic breast cells than docetaxel and doxorubicin. Strikingly, exposure of doxorubicin-resistant MCF-7-DoxR cells to LQB-223 resulted in suppression of cell viability and proliferation in levels comparable to MCF-7. Of note, MCF-7-DoxR cells have an elevated expression of the P-glycoprotein efflux pump when compared to MCF-7.
Together, these results show that LQB-223 mediates cytotoxic effects in sensitive and resistant breast cancer cells, while presenting low toxicity to non-neoplastic cells. The new compound might represent a potential strategy to induce toxicity in breast cancer cells, especially chemoresistant cells.
KeywordsBreast cancer Drug resistance LQB-223 compound Toxicity Chemotherapeutic agents
This work was supported by grants from Instituto Nacional de Ciência e Tecnologia (INCT), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Amparo à Pesquisa do Rio de Janeiro (FAPERJ) and Programa de Oncobiologia. We would also like to thank Matheus Andrade Rajão for technical support.
Compliance with ethical standards
Conflict of interest
The authors confirm that this article content has no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- Burnell M et al (2010) Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol 28:77–82. doi: 10.1200/JCO.2009.22.1077 CrossRefPubMedGoogle Scholar
- Chintamani, Singh JP, Mittal MK, Saxena S, Bansal A, Bhatia A, Kulshreshtha P (2005) Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer–a prospective clinical study. World J Surg Oncol 3:61 doi: 10.1186/1477-7819-3-61
- Kim CW, Asai D, Kang JH, Kishimura A, Mori T, Katayama Y (2015) Reversal of efflux of an anticancer drug in human drug-resistant breast cancer cells by inhibition of protein kinase Calpha (PKCalpha) activity Tumour Biol doi: 10.1007/s13277-015-3963-4
- Maia RC et al (2011) LQB-118, a pterocarpanquinone structurally related to lapachol [2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone]: a novel class of agent with high apoptotic effect in chronic myeloid leukemia cells. Invest New Drugs 29:1143–1155. doi: 10.1007/s10637-010-9453-z CrossRefPubMedGoogle Scholar
- Martino T, Magalhaes FC, Justo GA, Coelho MG, Netto CD, Costa PR, Sabino KC (2014) The pterocarpanquinone LQB-118 inhibits tumor cell proliferation by downregulation of c-Myc and cyclins D1 and B1 mRNA and upregulation of p21 cell cycle inhibitor expression. Bioorganic Med Chem 22:3115–3122. doi: 10.1016/j.bmc.2014.04.025 CrossRefGoogle Scholar
- Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, Jones A (2010) Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 10:337. doi: 10.1186/1471-2407-10-337 CrossRefPubMedPubMedCentralGoogle Scholar
- Trape AP, Katayama ML, Roela RA, Brentani H, Ravacci GR, de Araujo Lima L, Brentani MM (2012) Gene expression profile in response to doxorubicin-rapamycin combined treatment of HER-2-overexpressing human mammary epithelial cell lines. Mol Cancer Ther 11:464–474. doi: 10.1158/1535-7163.MCT-11-0033 CrossRefPubMedGoogle Scholar